Estudio de las características metabólicas, hormonales e inmunoinflamatorias de mujeres con síndrome de ovarios poliquísticos con o sin obesidad. Análisis del impacto del tratamiento con atorvastatina

Laburpena

Polycystic ovary syndrome is characterized by hyperandrogenism, chronic anovulation and infertility and is one of the most frequent endocrine disorders in women. Moreover, a high proportion of these women have obesity, insulin resistance and metabolic syndrome characteristics. The improvement of metabolic anomalies, especially those related to insulin resistance, by changes in the lifestyle or pharmacological interventions, has shown to improve hyperandrogenism and infertility. This shows a close relation between reproductive and metabolic alterations in polycystic ovary syndrome. The inhibitors of a 3-hydroxi-3-mehtylglutaryl enzyme A reductase, known as statins, have shown a reduction of morbidity and mortality in cardiovascular disease. They also have others non lipid effects, which suggest beneficial effects in hypertensive patients with normal lipids concentrations as anti-inflammatory effects in patients with chronic diseases. Others beneficial effects of statins include modifications in plasma interleukins and inflammation marker concentrations, improve of endothelial dysfunctions, increase of nitric oxide bioavailable, antioxidant properties, inhibition of inflammatory response and atherosclerotic plaque stabilization.